Mitochondrial Complex I Modulators for Arthritis Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic musculoskeletal diseases like rheumatoid arthritis primarily focus on reducing symptoms and inflammation but fail to address structural progression and functional decline, leading to ongoing disability and poor quality of life, as they suppress normal bone dynamics and repair processes.
Innovation Solution
Mitochondrial Complex I modulator (MCIM) compounds are used to modulate mitochondrial activity, creating a wound repair-like microenvironment that controls inflammation and initiates tissue repair, promoting structural reversal of damage and improving functional disability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional anti-inflammatory drugs (NSAIDs, DMARDs, bDMARDs) are used to reduce inflammation and symptoms, then inflammatory biomarkers and symptom severity are improved, but structural progression (bone erosion, cartilage loss) and functional disability continue to worsen
Solution Approach 1:
The patent applies this principle by using low-dose glucocorticoids (typically used for symptom control) in a novel way: combining them with DMARDs to actively promote bone and cartilage repair. The glucocorticoids, when used at low doses alongside disease-modifying agents, convert their potential harm (bone suppression) into benefit (tissue repair promotion) by creating a favorable microenvironment for regeneration while the DMARDs control the underlying inflammation.
Solution Approach 2:
The patent changes the dosage parameter of glucocorticoids from conventional high/standard doses to low doses, and combines this with specific DMARDs. This parameter change transforms the effect of glucocorticoids from purely suppressive to reparative, allowing them to promote tissue healing without excessive immunosuppression. The combination therapy parameters (low-dose glucocorticoid + DMARD) achieve both symptom control and structural protection.
2Object-affected harmful factors
If high-dose immunosuppressants are used to achieve remission, then disease activity is reduced, but normal bone dynamics and repair processes are suppressed
Solution Approach 1:
The patent applies local quality by creating different microenvironments in different tissues: in inflamed areas, DMARDs suppress immune activity to control disease, while in bone and cartilage tissues, low-dose glucocorticoids create a reparative microenvironment that promotes healing. This localized differential effect allows simultaneous disease control and tissue repair without global immunosuppression.
Solution Approach 2:
The patent uses low-dose glucocorticoids to preliminarily prepare the tissue microenvironment for repair before or during DMARD therapy. By预先 creating favorable conditions (reducing excessive inflammation, modulating immune cell activity) in the bone and cartilage microenvironment, the tissue becomes more receptive to repair processes initiated by the combination therapy.
3Ease of operation
If current treatment regimens are used to control symptoms, then patient comfort is improved, but quality of life and functional capacity continue to decline
Solution Approach 1:
The patent makes the treatment regimen multi-functional: the combination of low-dose glucocorticoids with DMARDs simultaneously achieves symptom control (anti-inflammatory effect), structural protection (inhibiting bone erosion and cartilage loss), and active tissue repair (promoting bone and cartilage regeneration). This universal approach addresses multiple aspects of disease management in one therapy, improving both comfort and functional outcomes.
Solution Approach 2:
The low-dose glucocorticoid acts as an intermediary between the DMARDs and the damaged tissues. While DMARDs control systemic inflammation, the glucocorticoid mediates local effects in bone and cartilage, creating a favorable microenvironment that enhances repair processes. This intermediary role allows the combination therapy to achieve both symptom control and functional improvement.
Data Source
Figure 1
Figure 2A~2D
Figure 3A~3B
AI summary
The invention provides mitochondrial complex I modulator (MCIM) compounds, which find utility in the treatment of arthritis, such as RA. The MCIM compounds find further utility in the treatment of physical functional decline and physical disabilities, such as age-related functional decline and disabilities. Treatment with MCIM compounds repair damage caused by arthritic disease and functional decline to improve patient quality of life.